L
Leo F. Faucette
Researcher at GlaxoSmithKline
Publications - 37
Citations - 4111
Leo F. Faucette is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: In vivo & Mutant. The author has an hindex of 24, co-authored 37 publications receiving 4006 citations. Previous affiliations of Leo F. Faucette include Smith, Kline & French.
Papers
More filters
Journal ArticleDOI
Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity.
William Dennis Kingsbury,Jeffrey C. Boehm,Dalia R. Jakas,K. G. Holden,Sidney M. Hecht,Gregory Gallagher,Mary Jo Caranfa,Francis L. McCabe,Leo F. Faucette,Randall K. Johnson,Robert P. Hertzberg +10 more
TL;DR: 9-[(dimethylamino)methyl]-10-hydroxycamptothecin (4, SK&F 104864) for development as an antitumor agent demonstrated broad-spectrum activity in preclinical tumor models and is currently undergoing Phase I clinical trials in cancer patients.
Journal ArticleDOI
Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway
Priya Chaturvedi,Wai K Eng,Yuan Zhu,Michael R. Mattern,Rubin Mishra,Mark R. Hurle,Xiaolong Zhang,Roland S. Annan,Quinn Lu,Leo F. Faucette,Gilbert F. Scott,Xiaotong Li,Steven A. Carr,Randall K. Johnson,James D. Winkler,Bin-Bing S. Zhou +15 more
TL;DR: Results suggest that Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway and might not only delay mitotic entry, but also increase the capacity of cultured cells to survive after treatment with γ-radiation or with the topoisomerase-I inhibitor topotecan.
Journal Article
Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin.
TL;DR: The cytotoxic effects of camptothecin are discussed in terms of the drug extending the lifetime of a topoisomerase I-DNA covalent intermediate, which is recognized as DNA damage by a DNA repair system.
Journal ArticleDOI
Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity.
Robert Cafferkey,Peter R. Young,Megan M. McLaughlin,Derk J. Bergsma,Yigal Koltin,Ganesh M. Sathe,Leo F. Faucette,Wai-Kwong Eng,Randall K. Johnson,George P. Livi +9 more
TL;DR: Genomic disruption of DRR1 in a mutant haploid strain restored drug sensitivity and demonstrated that the gene encodes a nonessential function, which supports the idea that FKBP12 and rapamycin form a toxic complex that corrupts the function of other cellular proteins.
Journal Article
Evaluation of the in Vivo Antitumor Activity and in Vitro Cytotoxic Properties of Auranofin, a Coordinated Gold Compound, in Murine Tumor Models
Christopher K. Mirabelli,Randall K. Johnson,Chiu Mei Sung,Leo F. Faucette,Katharine Muirhead,Stanley T. Crooke +5 more
TL;DR: Evaluation of the effects of auranofin in vitro demonstrated that survival curves for B16 melanoma cells as measured by the clongenic and dye exclusion assays were exponential and monophasic.